Microbot Medical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Microbot Medical Inc. on August 6, 2026. The report discloses the entry into a material definitive agreement regarding executive compensation.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed relates to executive compensation:
- Executive Salary Adjustment: The annual base salary for Chief Financial Officer Rachel Vaknin was increased to NIS 864,000 (approximately $288,000 USD based on a 3:1 exchange rate).
- Effective Date: The salary increase is effective as of August 1, 2026.
Material Changes
The material change reported is the execution of Addendum #4 to the Employment Agreement with the CFO. This represents a modification to the terms of employment rather than a change in the company's operational or financial performance relative to a prior period.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies beyond the standard disclosure of the employment agreement terms. No unusual items were reported.
Key Facts for Investor Verification
- Verify the impact of the increased CFO compensation on the company's operating expenses in future quarterly reports.
- Confirm the current exchange rate used for the USD conversion of the NIS salary, as the filing notes a "presumed" 3:1 rate.
- Review the full text of Addendum #4 (Exhibit 10.1) for any additional terms, such as bonuses or equity grants, not detailed in the summary.